Date: July 1, 2021
Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST)
What’s driving precision-medicine innovations? New advances in gene and cell therapy manufacturing, along with more elegant genome editing tools.
And what’s the biggest challenge? Deriving consistent, safe gene and cell therapy products is a major hurdle, as the process has the potential for unintended modifications that could hamper full translation into the clinic.
Get a first look at the Genomic Vision Quality Control Assay (QCA) for therapeutic genome editing and biomanufacturing. This state-of-the-art assay provides direct visualization of non-amplified single DNA molecules, enabling digital quantification of gene editing outcomes, including transgene copy numbers and integration patterns.
In this talk, you’ll discover how to use QCA to:
- Quantify the efficiency and fidelity of gene editing therapies to deliver safe therapies to clinicians.
- Characterize transgene integration patterns with high sensitivity and quantitative results to precisely monitor the quality of cell lines
You can then assess their stability throughout the manufacturing process: an essential step in the developing and producing biologics.
- Summarize how molecular combing can be used to ensure consistent, safe gene and cell therapy products
- Learn how the Genomic Vision Quality Control Assay (QCA) can be an effective tool in therapeutic genome editing and biomanufacturing
- July 1 - Quality control advancements in therapeutic genome editing and biomanufacturing - Dr. Imen Mestiri
- Therapeutic genome editing, Biomanufacturing
Webinars will be available for unlimited on-demand viewing after live event.